Eastern Cooperative Oncology Group

描述（由申请人提供）：梅奥诊所是东方肿瘤合作组织成员，已有30年的历史。这项拨款申请的目的是支持梅奥诊所继续成为东部肿瘤合作组织的成员。目标是为了更好地了解恶性肿瘤，更好地了解恶性疾病的相关问题，开发改进的恶性疾病治疗方案，提高恶性疾病患者的生存率。梅奥诊所拥有资源、人员、设施和患者群体，可以为ECOG的研究项目做出强有力的贡献。随着梅奥医疗实践的持续增长和发展，我们期待重大协议的签署和科学贡献。ECOG的附属机构及其强大的治疗和辅助实验室项目为梅奥诊所、其研究人员、其附属的区域癌症项目以及参与这些研究活动的大量恶性疾病患者提供了重大利益。这项拨款提案的具体目的是支持梅奥诊所ECOG研究活动的以下方面，其中包括：1.评估新的方案设计和治疗方案，以提供整个小组范围内恶性疾病的ECOG II期和III期治疗方案；2)协调并参与与恶性疾病ECOG治疗方案相关的辅助实验室相关研究；3)血液系统恶性肿瘤预后新因素及指标的发展；4.)参与特定疾病的积累和活动；5.)和参与西非经济共同体的行政活动。这些目标将被纳入临床试验基础设施，重点是机构病人的护理质量，临床研究助理（CRA）的发展，和教师的发展。

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group for 30 years. The purpose of this grant application is to support the continued membership of the Mayo Clinic in the Eastern Cooperative Oncology Group. The goals are directed toward a greater understanding of malignancies, a better understanding of related problems in malignant diseases, development of improved treatment programs in malignant diseases, and improved patient survival in malignant diseases. Mayo Clinic has the resources, personnel, facilities, and patient population to facilitate strong contributions to the research programs of ECOG. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contributions. The ECOG affiliation with its strong treatment and ancillary laboratory programs which have evolved provide major benefits to Mayo Clinic, its investigators, its affiliated regional cancer programs, and the large group of patients with malignant diseases who are involved in these research activities. The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities which include the following: 1.) evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and Phase III treatment protocols in malignant diseases; 2.) coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG treatment protocols in malignant diseases; 3.) development of new prognostic factors and indexes in hematologic malignancies; 4.) participation in disease-specific accrual and activities; 5.) and participation in administrative activities in ECOG. These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development.